|
gptkbp:instanceOf
|
gptkb:antiretroviral_therapy
gptkb:non-nucleoside_reverse_transcriptase_inhibitor
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
J05AG05
|
|
gptkbp:bioavailability
|
44%
|
|
gptkbp:brand
|
gptkb:Edurant
|
|
gptkbp:CASNumber
|
500287-72-9
|
|
gptkbp:category
|
gptkb:antiviral_drug
gptkb:HIV_drug
|
|
gptkbp:chemicalClass
|
diarylpyrimidine
|
|
gptkbp:combines
|
emtricitabine
tenofovir
|
|
gptkbp:contraindication
|
severe hepatic impairment
concurrent use with proton pump inhibitors
|
|
gptkbp:developedBy
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:eliminationHalfLife
|
45 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstBook
|
No
|
|
gptkbp:hasMolecularFormula
|
C22H18N6
|
|
gptkbp:hasSMILES
|
C1=CC=C(C=C1)C2=NC3=C(N2)N=CN=C3C4=CC=CC=C4C#CC5=CC=CC=N5
|
|
gptkbp:KEGGID
|
D09622
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits HIV-1 reverse transcriptase
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:patent
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:pregnancyCategory
|
B (US)
B1 (Australia)
|
|
gptkbp:proteinBinding
|
99.7%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL164522
6451164
4952322
DB08864
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:depression
nausea
headache
rash
insomnia
|
|
gptkbp:synonym
|
TMC278
|
|
gptkbp:UNII
|
N8PK4M7P7D
|
|
gptkbp:usedFor
|
HIV-1 infection
|
|
gptkbp:bfsParent
|
gptkb:DB06287
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rilpivirine
|